BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Tirzepatide: trial readouts and FDA decisions
3 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 9 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Eli Lilly and Company, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Hudson Biotech, Ikaria Bioscience Pty Ltd, Innovent Biologics (Suzhou) Co. Ltd., Hoffmann-La Roche, Novo Nordisk A/S. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-02-04 est. | P2 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | NCT07521631 Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes | Obesity | recruiting | 372 |
| 2027-02-14 est. | P3 | Hudson Biotech | NCT07481747 Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities | recruiting | 2539 |
| 2027-02-15 est. | P1/P2 | Ikaria Bioscience Pty Ltd | NCT07245771 Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination | Obesity &Amp; Overweight | recruiting | 104 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06962280 A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes; Obesity; Overweight | active not recruiting | 465 |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06914895 A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Type 1 Diabetes; Obesity; Overweight | active not recruiting | 905 |
| 2026-11 est. | P3 | Eli Lilly and Company LLY | NCT06662383 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | Obesity | active not recruiting | 800 |
| 2026-09-30 est. | P1/P2 | Innovent Biologics (Suzhou) Co. Ltd. | NCT07000955 Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity | Obesity | active not recruiting | 98 |
| 2026-09-03 | P2 | Hoffmann-La Roche | NCT06965413 A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants W | Obesity; Overweight; Overweight With One Weight Related Comorbidity | active not recruiting | 285 |
| 2026-07-06 | P2 | Eli Lilly and Company LLY | NCT05536804 A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes | Overweight; Obesity; Chronic Kidney Disease; Type 2 Diabetes; T2D | completed | 134 |
| 2026-07-01 | P2 | Eli Lilly and Company LLY | NCT06603571 A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight W | Obesity; Overweight | completed | 367 |
| 2026-06-02 | P3 | Novo Nordisk A/S NVO | NCT06534411 A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGL | Diabetes Mellitus, Type 2 | completed | 1023 |
| 2026-06-02 | P3 | Eli Lilly and Company LLY | NCT06075667 A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Obesity; Overweight | active not recruiting | 160 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.